Catabasis and Sarepta join forces to explore drug combo for Duchenne muscular dystrophy
Hot on the heels of finally gaining US Food and Drug Administration approval for its Exondys 51 (eteplirsen), US biotech Sarepta Therapeutics (Nasdaq: SRPT) had entered into a research collaboration with clinical-stage biopharma company Catabasis (Nasdaq: CATB) to explore a combination drug treatment approach for Duchenne muscular dystrophy (DMD).
The two companies will contribute their respective expertise to study an exon-on-skippingskipping treatment developed by Sarepta, together with an oral NF-kB inhibition treatment developed by Catabasis in a mouse model of DMD.
Even though no financial terms were disclosed, news of the collaboration sent Catabasis’ shares rocketing as much as 58% to $7.02, their highest point since June, as the company’s chief executive noted that
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze